Prudential Financial Inc. Has $260,000 Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Prudential Financial Inc. lessened its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 70.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,366 shares of the medical instruments supplier's stock after selling 67,000 shares during the period. Prudential Financial Inc. owned approximately 0.07% of AngioDynamics worth $260,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ANGO. Connor Clark & Lunn Investment Management Ltd. grew its position in AngioDynamics by 69.0% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 389,053 shares of the medical instruments supplier's stock valued at $3,564,000 after purchasing an additional 158,897 shares in the last quarter. Royce & Associates LP increased its position in shares of AngioDynamics by 13.5% during the 4th quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier's stock worth $10,254,000 after purchasing an additional 133,312 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in AngioDynamics by 28.7% during the third quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier's stock worth $4,304,000 after buying an additional 123,271 shares during the last quarter. Principal Financial Group Inc. bought a new stake in AngioDynamics in the fourth quarter valued at approximately $879,000. Finally, XTX Topco Ltd acquired a new stake in AngioDynamics during the 3rd quarter valued at $582,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Stock Performance

Shares of AngioDynamics stock traded down $0.19 during midday trading on Wednesday, hitting $9.39. 35,276 shares of the company traded hands, compared to its average volume of 562,783. AngioDynamics, Inc. has a 12 month low of $5.47 and a 12 month high of $13.50. The stock has a market cap of $381.10 million, a price-to-earnings ratio of -1.67 and a beta of 0.52. The firm's fifty day moving average price is $9.75 and its 200-day moving average price is $8.98.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.16. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The firm had revenue of $72.00 million for the quarter, compared to analyst estimates of $70.30 million. The company's revenue for the quarter was down 4.3% compared to the same quarter last year. Equities research analysts forecast that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and set a $16.00 target price (up previously from $15.00) on shares of AngioDynamics in a research note on Monday, April 7th.

Insider Buying and Selling

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the business's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. The trade was a 8.85 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.40% of the stock is currently owned by insiders.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.